UCB SA (VIE:UCB)

Austria flag Austria · Delayed Price · Currency is EUR
160.60
+9.70 (6.43%)
At close: Apr 30, 2025, 5:30 PM CET
29.78%
Market Cap 30.63B
Revenue (ttm) 6.15B
Net Income (ttm) 1.07B
Shares Out n/a
EPS (ttm) 5.48
PE Ratio 28.76
Forward PE n/a
Dividend 0.97 (0.65%)
Ex-Dividend Date Apr 25, 2025
Volume 241
Average Volume 24
Open 159.65
Previous Close 150.90
Day's Range 159.65 - 161.95
52-Week Range 120.05 - 197.55
Beta n/a
RSI 56.16
Earnings Date Apr 23, 2025

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spra... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1925
Employees 9,378
Stock Exchange Vienna Stock Exchange
Ticker Symbol UCB
Full Company Profile

Financial Performance

In 2024, UCB SA's revenue was 6.15 billion, an increase of 18.72% compared to the previous year's 5.18 billion. Earnings were 1.07 billion, an increase of 210.50%.

Financial Statements

News

There is no news available yet.